{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T03:04:01Z","timestamp":1779764641073,"version":"3.53.1"},"reference-count":4,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:p>We conducted a retrospective cohort study across four UK centres to establish whether therapeutic drug monitoring and dose escalation of adalimumab up to 80\u2005mg weekly improved patient outcomes. This study represents one of the largest cohorts examining therapeutic drug monitoring and high-dose adalimumab in patients with hidradenitis suppurativa. Unlike previous studies, we did not observe significant mean improvements across standardized outcome measures, despite over 50% of patients being assessed by their clinicians as showing overall improvement.<\/jats:p>","DOI":"10.1093\/ced\/llag044","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:42:10Z","timestamp":1769258530000},"page":"1104-1106","source":"Crossref","is-referenced-by-count":0,"title":["Adalimumab 80\u2005mg weekly dose escalation for hidradenitis suppurativa: a multicentre retrospective cohort study incorporating therapeutic drug monitoring"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4521-2907","authenticated-orcid":false,"given":"Hannah E","family":"Wainman","sequence":"first","affiliation":[{"name":"Centre for Applied Excellence in Skin and Allergy Research, University of Bristol , Bristol ,","place":["UK"]},{"name":"Bristol Dermatology Centre, Bristol Royal Infirmary, University Hospitals Bristol and Weston NHS Foundation Trust , Bristol ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9244-6530","authenticated-orcid":false,"given":"Ser Ling","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-6114","authenticated-orcid":false,"given":"Donal","family":"O\u2019Kane","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Belfast Health and Social Care Trust , Belfast ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mehrtens","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R","family":"Ingram","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, Cardiff University , Cardiff ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026052522574014800_llag044-B1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"2026052522574014800_llag044-B2","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1111\/ajd.14465","article-title":"Efficacy of high dose adalimumab for the management of hidradenitis suppurativa: a systematic review","volume":"66","author":"Jones","year":"2025","journal-title":"Australas J Dermatol"},{"issue":"Suppl 2","key":"2026052522574014800_llag044-B3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"2026052522574014800_llag044-B4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag044\/66593880\/llag044.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1104\/66593880\/llag044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/6\/1104\/66593880\/llag044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T02:57:49Z","timestamp":1779764269000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/6\/1104\/8442813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":4,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag044","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,1,28]]}}}